RHJA
TRIB

Rice Hall James & Associates’s Trinity Biotech TRIB Stock Holding History

Rice Hall James & Associates’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-878
Closed -$2.38M – 311
2015
Q2 		$2.38M Sell
878
-9
-1% -$23.4K 0.14% 167
2015
Q1 		$2.56M Buy
887
+78
+10% +$216K 0.15% 155
2014
Q4 		$2.13M Sell
809
-3
-0.4% -$7.76K 0.13% 196
2014
Q3 		$2.23M Sell
812
-12
-1% -$39K 0.16% 176
2014
Q2 		$2.85M Sell
824
-8
-1% -$28.4K 0.19% 141
2014
Q1 		$3.02M Buy
832
+500
+151% +$1.97M 0.22% 123
2013
Q4 		$1.25M Buy
+332
New +$1.2M 0.09% 210

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $856M AUM 70.44% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Rice Hall James & Associates's TRIB Position: Q3 2015 in Review

Rice Hall James & Associates sold out of Trinity Biotech (TRIB) in Q3 2015, closing a stake of 878 shares — an estimated $2.38M sold.

Rice Hall James & Associates first reported a position in TRIB in Q4 2013 and held it in 7 quarters. The position peaked at $3.02M in Q1 2014. 92 funds tracked by Wall St. Rank hold TRIB as of Q3 2015.

  • Rice Hall James & Associates reported no remaining Trinity Biotech position as of Q3 2015 after selling out during the quarter.
  • Rice Hall James & Associates sold 878 Trinity Biotech shares in Q3 2015, an estimated $2.38M.
  • Rice Hall James & Associates first reported a position in Trinity Biotech in Q4 2013 and held it in 7 quarters.
  • Rice Hall James & Associates's Trinity Biotech position peaked at $3.02M in Q1 2014.
  • 92 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2015.

Based on Rice Hall James & Associates's 13F filing for Q3 2015, filed 30 Oct 2015.